From Valneva to the CEO position at NorthX – “I saw it as a great opportunity”

A new cell therapy for leukaemia, a vaccine in tablet form against cholera, and a proprietary mRNA line with the potential capacity to supply the entire Nordic ...

ZEISS introduces the new Smartzoom 100

The future of digital microscopy for efficient optical inspections.

Merck KGaA acquires American company in €3.0 billion deal

Germany’s Merck is completing the acquisition of Springwork Therapeutics for 3 billion euros.

Studie: Protein i urinen en biomarkör för demensrisk

Höga nivåer av proteinet albumin i urinen indikerar en ökad risk för att utveckla demens, enligt en stor studie från Karolinska institutet, KI.

The physician at the tech giant: “Observations in the emergency room made my mind up”

When Nasim Farrokhnia was in third grade at school in Tehran, the capital of Iran, her father gave her a book about Marie Curie, which soon became her favourite...

“What is important is to create an overview and understanding from different perspectives”

Scientist Jochen Schwenk analyses blood proteins using proteomics to improve our understanding of disease and health. This year, he is moderating the Lab & Diag...

Nocebo – the evil twin that makes you feel worse

The placebo effect is well known in healthcare, but not so its opposite: nocebo. “The effect is small, but it can have major repercussions,” says Uppsala resear...

One System, Three Contrasting Techniques

ZEISS Axioscan 7 clinical - your digital slide scanner for diagnostics and clinical research.

AstraZeneca´s Trixeo approved in the UK using propellant with near-zero Global Warming Potential

AstraZeneca has received approval in the United Kingdom for its inhaled respiratory medicine Trixeo Aerosphere with a new propellant that is reported to reduce ...

Double up for Korbinian Löbmann

This year, Korbinian Löbmann will moderate the New Updates in Drug Formulation & Bioavailability meeting in Copenhagen for the fifth time. Furthermore, he will ...

The race between new alzheimer’s drugs Kisunla and Leqembi heats up

Kisunla or Leqembi? The rivalry between Eli Lilly and Bioarctic is intensifying. Where one drug gains approval, the other falls behind. Here's a look at the mar...

Eli Lilly requests re-examination of Alzheimer's drug recommendation

Eli Lilly has requested that the EMA re-examine its opinion on the company's Alzheimer's drug, Kisunla, the agency announced on Friday.

Reduced heat transfer to the media with media-separated valves

In laboratory automation, many liquids are used that react sensitively to heat. One possible factor for the transfer of heat to the fluid are media-separated so...

Extremely high sample throughput rates

Precision and reliability in automated liquid handling

Agreement in the EU on eight years of data exclusivity for new medicines

New pharmaceuticals will be covered by eight years of data exclusivity, according to the proposed new pharmaceutical legislation that EU countries have now agre...

Study names with an attitude – more important than you might think

Ironman, T-rex, Star-Trek. Popcorn, Proper, Scout. Nope, these are neither fantasy films nor dog names. They’re the names of ongoing cancer studies in Sweden.

CT technology for when the inside matters

ZEISS METROTOM 1 now at #HandsOnMetrology.

A surprising discovery about the immune system in cases of cancer

Professor Göran Jönsson is trying to understand why some patients benefit from immunotherapies while others don’t. A couple of years ago, he made a surprising d...

Sobi announces agreement with Enable Injections

Swedish biopharma Sobi has entered into an international development and distribution agreement with US drug delivery company Enable Injections.

Study: Chat GPT is more empathetic than doctors

The AI tool Chat GPT is not only more accurate when it comes to answering patient questions – the chatbot is also perceived as almost 10 times more empathetic t...

New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Copenhagen (2026)

Xbrane enters licensing agreement with Indian generics giant

Swedish biosimilar developer Xbrane Biopharma and the Indian company Intas Pharmaceuticals have entered into a license and co-development agreement.

Founder of Bioarctic, Lars Lannfelt, is honoured: “I want to create something for the future”

It´s like a scientist’s dream: to be the world’s first with a drug that genuinely affects one of our major diseases. Lars Lannfelt and his company Bioarctic hav...

Neanderthal gene variants may cause Viking disease

A new study suggests that the so-called Viking disease, which affects the hand function in many older people, may be linked to gene variants inherited from Neanderthals.